Engineering microbial therapeutics for metabolic disorders: synthetic biology strategies and future direction
Current Opinion in Biotechnology · 2026
DOI: 10.1016/j.copbio.2026.103440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Opinion in Biotechnology, 2026. Verfasst von Yani Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, PR China; Shanghai Frontiers Scie…. Hauptthemen laut MEDLINE: Synthetic Biology, Metabolic Diseases, Metabolic Engineering, Probiotics. Die Arbeit nennt 78 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Metabolic disorders, including type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis, etc., are an escalating global health challenge with substantial clinical and socio-economic burdens. Conventional pharmacological therapies are constrained by short-term efficacy, instability, and energy-intensive production. This review aims to evaluate how synthetic biology enables engineered probiotics and microbial systems as self-regulating, living therapeutics that integrate precision treatment with sustainable, bio-based production. Such systems can secrete therapeutic molecules, degrade harmful metabolites, remodel host metabolic microenvironments, and respond to physiological signals to achieve adaptive, feedback-controlled interventions. By exploiting versatile microbial hosts and low-energy fermentation, they minimize chemical waste and carbon footprint. We also discussed preclinical studies demonstrating restored glucose and lipid homeostasis, modulation of appetite, and attenuation of inflammation. Collectively, our review highlights that synthetic biology exemplifies a transformative, sustainable paradigm for metabolic disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, PR China; Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji Unive…
Förderung
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Li, Y., Wang, Y., Zhu, S., & Tang, Z. (2026). Engineering microbial therapeutics for metabolic disorders: synthetic biology strategies and future direction. Current Opinion in Biotechnology. https://doi.org/10.1016/j.copbio.2026.103440
Vancouver
Li Y, Wang Y, Zhu S, Tang Z. Engineering microbial therapeutics for metabolic disorders: synthetic biology strategies and future direction. Current Opinion in Biotechnology. 2026. doi:10.1016/j.copbio.2026.103440
BibTeX
@article{Li2026,
author = {Li, Yani and Wang, Yanting and Zhu, Siyu and Tang, Zhongmin},
title = {Engineering microbial therapeutics for metabolic disorders: synthetic biology strategies and future direction},
journal = {Current Opinion in Biotechnology},
year = {2026},
doi = {10.1016/j.copbio.2026.103440}
}
EUVIMED